 SAN DIEGO, Aug. 9, 2021 PRNewswire -- Heron Therapeutics, Inc. Nasdaq: HRTX, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and six months ended June 30, 2021 and highlighted recent corporate updates. Recent Corporate Updates Acute Care Franchise ZYNRELEF Now Available: In May 2021, the U.S. Food and Drug Administration FDA approved the Companys New Drug Application NDA for ZYNRELEF bupivacaine and meloxicam extended-release solution. 